

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab)
Recombinant Antibody
Catalog # APR10073****Specification**

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P32970
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.36 KDa

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Additional Information**Target/Specificity**

TNFSF7 / CD27L / CD70

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Protein Information**Name** CD70 ([HGNC:11937](#))**Function**

Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed:28011863, PubMed:28011864, PubMed:8387892). The CD70-CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed:28011863, PubMed:28011864).

Cellular Location


Cell membrane; Single-pass type II membrane protein

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Images




Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) is more than 95%, determined by SEC-HPLC.



Immobilized human CD70 FC at 4 µg/mL can bind Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) $EC_{50}=0.08279$ µg/mL



HL-60 cells were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, $EC_{125}=0.2727$ µg/mL